| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA797: Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) |
|
Medicine details |
|
| Medicine name | enfortumab vedotin (Padcev®) |
| Formulation | 20 mg powder for concentrate for solution for infusion |
| Reference number | 4684 |
| Indication | As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor‑1 or programmed death‑ligand 1 inhibitor |
| Company | Astellas Pharma Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/05/2022 |
| NICE guidance | |